Clinical Trials Logo

Clinical Trial Summary

This is a multiple-sites, double-blinded, randomized, controlled, parallel-designed, cross-over study among healthy preschoolers with 5 days consumption of A2 or A1 milk to compare the effects on gut inflammation, gastrointestinal symptoms and behavioral well-being.


Clinical Trial Description

Gut inflammation is reflected by serum C-Reactive Protein (CRP), hemoglobin (HB), interleukin-4 (IL-4), Immunoglobulin G (IgG), Immunoglobulin E (IgE), Immunoglobulin G1 (IgG1), Immunoglobulin G2a (IgG2a), β-Casomorphin-7 (BCM-7), Glutathione, calcium (Ca), iron (Fe) and zinc (Zn) concentration; gastrointestinal (GI) symptoms are measured via Visual Analog Scale (VAS) for gut tolerance, including borborygmus, bloating, break wind, abdominal pain, and diarrhea; behavioral well-being is assessed using Subtle Cognitive Impairment Test (SCIT).

The total duration of study was 24 weeks, including subject enrollment, study intervention, laboratory testing, and providing clinical study report. The cross-over study consisted of 5 days of each product intervention; 10 days of wash-out in phase 1 and phase 2, respectively; and then followed by 6 weeks of statistical analysis and clinical report completion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03081845
Study type Interventional
Source a2 Milk Company Ltd.
Contact
Status Completed
Phase Phase 4
Start date September 13, 2016
Completion date January 20, 2017

See also
  Status Clinical Trial Phase
Completed NCT03399903 - Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection Phase 1/Phase 2
Active, not recruiting NCT04497727 - Gut Organoid Study
Completed NCT02118402 - Iron and Prebiotics Fortification in Kenyan Infants N/A